NASH: The next untapped pharma market gives investors many options
(Reuters) - Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Fatty Liver Disease (FLD) | Health | Hemorrhoids | Liver | Liver Disease | Liver Transplant | Pharmaceuticals | Transplants | Urology & Nephrology